This is a Phase II Randomized Controlled PILOT clinical study. The purpose of this study is to explore the efficacy and safety of surufatinib and serplulimab in combination with albumin-paclitaxel and gemcitabine in the conversion therapy for patients with unresectable locally advanced pancreatic cancer. Furthermore, it compares the efficacy of surufatinib and serplulimab in combination with albumin-paclitaxel and gemcitabine to the albumin-paclitaxel and gemcitabine regimen in the conversion therapy for patients with unresectable locally advanced pancreatic cancer.
Written informed consent obtained from the patient prior to treatment.
Pathologically confirmed unresectable locally advanced pancreatic cancer, received no surgical therapy.
Age between 18 and 75 years at the time of study entry.
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
Participants diagnosed pancreatic cancer with distant metastases.
Participation in other antineoplastic drug clinical trials within 4 weeks prior to enrollment;
Previous systemic antitumor therapy (chemotherapy, radiation, targeted or immunoth, etc.).
Diagnosis of any second malignancy, except for adequately treated basal cell skin cancer or in situ carcinoma of the cervix uteri.